-
Mubritinib (TAK 165) Experimental Workflows
2026-09-05
Mubritinib (TAK 165) is most useful as a mechanistic probe of mitochondrial complex I, with distinct concentration strategies for chemotherapy-resistant AML and KSHV-positive primary effusion lymphoma. This workflow-led guide covers dosing, orthogonal readouts, HER2 interpretation, assay troubleshooting, and translational limitations.
-
Calpain Inhibition for Translational Neuroprotection
2026-09-05
MDL 28170 illustrates how selective calpain and cathepsin B inhibition can connect protease biology with synaptic plasticity, neuroprotection, and translational assay design. This thought-leadership perspective interprets recent BDNF/TrkB findings and outlines a rigorous workflow for evaluating calpain-dependent injury mechanisms.
-
Dual-Action Control of p38α Dephosphorylation
2026-09-04
The reference study shows that some kinase inhibitors do more than block p38α catalytic activity: they also reshape its activation loop to accelerate WIP1-mediated dephosphorylation. By combining biochemical assays with X-ray crystallography, the work introduces a conformational strategy for improving kinase-inhibitor potency and specificity while clarifying its current limits for inflammation research.
-
Carbenoxolone disodium Workflow Guide
2026-09-04
Carbenoxolone disodium is an 11β-hydroxysteroid dehydrogenase inhibitor for controlled cell- and tissue-based studies of glucocorticoid access, corticosterone metabolism, and gap junction communication. It is useful for mechanistic perturbation with appropriate vehicle, viability, and orthogonal controls, but it should not be treated as a selective probe or as evidence of in vivo efficacy.
-
METTL17, Mitochondrial Translation, and Ferroptosis
2026-09-03
The reference study identifies METTL17 as a mitochondrial regulator that links RNA methylation and mitochondrial protein translation to ferroptosis resistance in colorectal cancer. Its combination of cellular, molecular, and in vivo models suggests that suppressing METTL17 can expose a therapeutically relevant vulnerability in tumors dependent on mitochondrial function.
-
(S)-(+)-Dimindene maleate: Workflow Guide
2026-09-02
This guide explains how to plan experiments with (S)-(+)-Dimindene maleate, a dossier-described M2 muscarinic receptor antagonist with additional histamine H1 antagonism. It supports controlled receptor, autonomic, cardiovascular, and respiratory research workflows, but does not establish potency, selectivity margins, diagnostic utility, or medical use.
-
MOG (35-55): EAE Workflow and Assay Guide
2026-09-02
MOG (35-55) provides a defined antigenic trigger for reproducible experimental autoimmune encephalomyelitis, supporting both disease-model development and mechanistic neuroinflammation assays. This guide connects formulation, dosing, readout selection, and the PARP7–STAT1/STAT2 findings reported in recent multiple sclerosis research.
-
M344: Histone Deacetylase Inhibitor Workflow
2026-09-01
M344 is a cell-permeable histone deacetylase inhibitor for connecting chromatin remodeling with cancer-cell growth, differentiation, radiation response, and viral-latency assays. This practical guide covers dose selection, treatment timing, endpoint pairing, solubility control, and interpretation of toxicity-sensitive results.
-
Localized Muscle BDNF Directs Early NMJ Assembly
2026-09-01
The reference study identifies a spatially restricted signaling mechanism in which muscle-derived BDNF is trafficked to podosome-like structures and released in an activity- and calcium-dependent manner to initiate acetylcholine receptor clustering at developing neuromuscular junctions. By combining live-cell imaging, targeted perturbations, agrin-driven synapse models, and muscle-specific BDNF knockout mice, the work connects local neurotrophin processing with early postsynaptic assembly.
-
Halazone Workflows for Water and Sodium Channels
2026-08-31
Halazone is a practical water disinfection agent and an unusual electrophysiology probe, linking hypochlorous-acid chemistry with sodium-current modulation. This guide translates the evidence into fresh-solution preparation, rapid microbial testing, voltage-clamp workflows, and troubleshooting decisions.
-
Iptacopan: From Factor B Biology to Translation
2026-08-31
Iptacopan (LNP023) illustrates how selective factor B inhibition can connect complement mechanism, assay design, disease modeling, and clinical decision-making. This thought-leadership perspective examines alternative pathway C3bBb inhibition, the PNH proof-of-concept evidence, practical experimental parameters, competitive positioning, and the translational limits that researchers should address before extending findings across complement-mediated diseases.
-
Stiripentol and the Lactate–Epigenetic Axis
2026-08-30
Stiripentol offers translational researchers a mechanistically distinct way to interrogate LDH-dependent lactate flux, neuronal excitability, and the broader relationship between metabolism and epigenetic regulation. This article connects its epilepsy research applications with emerging lactate–histone lactylation findings while clearly separating validated evidence from forward-looking hypotheses.
-
S63845 MCL1 Inhibitor: Assay Workflow Guide
2026-08-29
S63845 enables target-focused interrogation of MCL1 dependence, mitochondrial apoptosis, and treatment resistance in cancer models. This workflow guide combines practical dosing, orthogonal readouts, combination-assay design, and troubleshooting for hematological and selected solid-tumor applications.
-
FUS–PARP1 Phase Separation and PAR Structure
2026-08-28
The 2024 study by Sukhanova and colleagues shows that FUS microphase separation with PARylated PARP1 depends not only on protein abundance, but also on polyamines, divalent cations, and PAR branching. Its comparative biochemical design provides a framework for interpreting how PARP1-generated condensates may organize DNA damage response processes, while also defining important limits for translating in vitro phase behavior to cancer models.
-
Omeprazole (A2845): H+,K+-ATPase Protocol
2026-08-28
Omeprazole (SKU A2845) provides a dossier-defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research, including stimulation-based acid formation assays and antiulcer activity study design. Its limited water and ethanol solubility requires DMSO-based handling and fresh solution preparation; it is for scientific research only and not for diagnostic, therapeutic, or medical use.